158 related articles for article (PubMed ID: 28658265)
1. Enhanced CDC of B cell chronic lymphocytic leukemia cells mediated by rituximab combined with a novel anti-complement factor H antibody.
Winkler MT; Bushey RT; Gottlin EB; Campa MJ; Guadalupe ES; Volkheimer AD; Weinberg JB; Patz EF
PLoS One; 2017; 12(6):e0179841. PubMed ID: 28658265
[TBL] [Abstract][Full Text] [Related]
2. Reduction of complement factor H binding to CLL cells improves the induction of rituximab-mediated complement-dependent cytotoxicity.
Hörl S; Bánki Z; Huber G; Ejaz A; Windisch D; Muellauer B; Willenbacher E; Steurer M; Stoiber H
Leukemia; 2013 Nov; 27(11):2200-8. PubMed ID: 23760402
[TBL] [Abstract][Full Text] [Related]
3. rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia.
Ge X; Wu L; Hu W; Fernandes S; Wang C; Li X; Brown JR; Qin X
Clin Cancer Res; 2011 Nov; 17(21):6702-11. PubMed ID: 21918174
[TBL] [Abstract][Full Text] [Related]
4. Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance.
Bannerji R; Kitada S; Flinn IW; Pearson M; Young D; Reed JC; Byrd JC
J Clin Oncol; 2003 Apr; 21(8):1466-71. PubMed ID: 12697868
[TBL] [Abstract][Full Text] [Related]
5. A DeImmunized chimeric anti-C3b/iC3b monoclonal antibody enhances rituximab-mediated killing in NHL and CLL cells via complement activation.
Peng W; Zhang X; Mohamed N; Inghirami G; Takeshita K; Pecora A; Nardone LL; Pincus SE; Casey LS; Spitalny GL
Cancer Immunol Immunother; 2005 Dec; 54(12):1172-9. PubMed ID: 15846490
[TBL] [Abstract][Full Text] [Related]
6. Combination of two anti-CD5 monoclonal antibodies synergistically induces complement-dependent cytotoxicity of chronic lymphocytic leukaemia cells.
Klitgaard JL; Koefoed K; Geisler C; Gadeberg OV; Frank DA; Petersen J; Jurlander J; Pedersen MW
Br J Haematol; 2013 Oct; 163(2):182-93. PubMed ID: 23927424
[TBL] [Abstract][Full Text] [Related]
7. Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy.
Bologna L; Gotti E; Da Roit F; Intermesoli T; Rambaldi A; Introna M; Golay J
J Immunol; 2013 Jan; 190(1):231-9. PubMed ID: 23225880
[TBL] [Abstract][Full Text] [Related]
8. Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement/rituximab interactions & clinical results in refractory CLL.
Klepfish A; Gilles L; Ioannis K; Rachmilewitz EA; Schattner A
Ann N Y Acad Sci; 2009 Sep; 1173():865-73. PubMed ID: 19758239
[TBL] [Abstract][Full Text] [Related]
9. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59.
Golay J; Lazzari M; Facchinetti V; Bernasconi S; Borleri G; Barbui T; Rambaldi A; Introna M
Blood; 2001 Dec; 98(12):3383-9. PubMed ID: 11719378
[TBL] [Abstract][Full Text] [Related]
10. Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement.
Baig NA; Taylor RP; Lindorfer MA; Church AK; Laplant BR; Pavey ES; Nowakowski GS; Zent CS
Leuk Lymphoma; 2012 Nov; 53(11):2218-27. PubMed ID: 22475085
[TBL] [Abstract][Full Text] [Related]
11. Monitoring of the Complement System Status in Patients With B-Cell Malignancies Treated With Rituximab.
Felberg A; Taszner M; Urban A; Majeranowski A; Jaskuła K; Jurkiewicz A; Stasiłojć G; Blom AM; Zaucha JM; Okrój M
Front Immunol; 2020; 11():584509. PubMed ID: 33329558
[TBL] [Abstract][Full Text] [Related]
12. Profiling of donor-specific immune effector signatures in response to rituximab in a human whole blood loop assay using blood from CLL patients.
Eltahir M; Fletcher E; Dynesius L; Jarblad JL; Lord M; Laurén I; Zekarias M; Yu X; Cragg MS; Hammarström C; Levedahl KH; Höglund M; Ullenhag G; Mattsson M; Mangsbo SM
Int Immunopharmacol; 2021 Jan; 90():107226. PubMed ID: 33316742
[TBL] [Abstract][Full Text] [Related]
13. Effect of alemtuzumab on neoplastic B cells.
Golay J; Manganini M; Rambaldi A; Introna M
Haematologica; 2004 Dec; 89(12):1476-83. PubMed ID: 15590398
[TBL] [Abstract][Full Text] [Related]
14. Resistance to complement activation, cell membrane hypersialylation and relapses in chronic lymphocytic leukemia patients treated with rituximab and chemotherapy.
Bordron A; Bagacean C; Mohr A; Tempescul A; Bendaoud B; Deshayes S; Dalbies F; Buors C; Saad H; Berthou C; Pers JO; Renaudineau Y
Oncotarget; 2018 Aug; 9(60):31590-31605. PubMed ID: 30167081
[TBL] [Abstract][Full Text] [Related]
15. Engineered anti-CD20 antibodies with enhanced complement-activating capacity mediate potent anti-lymphoma activity.
Natsume A; Shimizu-Yokoyama Y; Satoh M; Shitara K; Niwa R
Cancer Sci; 2009 Dec; 100(12):2411-8. PubMed ID: 19758394
[TBL] [Abstract][Full Text] [Related]
16. Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis.
Hu W; Ge X; You T; Xu T; Zhang J; Wu G; Peng Z; Chorev M; Aktas BH; Halperin JA; Brown JR; Qin X
Cancer Res; 2011 Mar; 71(6):2298-307. PubMed ID: 21252115
[TBL] [Abstract][Full Text] [Related]
17. Neutralization of (NK-cell-derived) B-cell activating factor by Belimumab restores sensitivity of chronic lymphoid leukemia cells to direct and Rituximab-induced NK lysis.
Wild J; Schmiedel BJ; Maurer A; Raab S; Prokop L; Stevanović S; Dörfel D; Schneider P; Salih HR
Leukemia; 2015 Aug; 29(8):1676-83. PubMed ID: 25710310
[TBL] [Abstract][Full Text] [Related]
18. Rituximab induces rapid blood repopulation by CLL cells mediated through their release from immune niches and complement exhaustion.
Borsky M; Hrabcakova V; Novotna J; Brychtova Y; Doubek M; Panovska A; Muller P; Mayer J; Trbusek M; Mraz M
Leuk Res; 2021 Dec; 111():106684. PubMed ID: 34438120
[TBL] [Abstract][Full Text] [Related]
19. Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies.
Le Garff-Tavernier M; Decocq J; de Romeuf C; Parizot C; Dutertre CA; Chapiro E; Davi F; Debré P; Prost JF; Teillaud JL; Merle-Beral H; Vieillard V
Leukemia; 2011 Jan; 25(1):101-9. PubMed ID: 20975664
[TBL] [Abstract][Full Text] [Related]
20. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
